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Background: Osteoarthritis (OA) is a common and debilitating chronic degenerative disease of the joints. Currently,
cell-based therapy is being explored to address the repair of damaged articular cartilage in the knee joint.
Methods: The in vitro differentiation potential of adult human bone marrow-derived, cultured, pooled, allogeneic
mesenchymal stromal cells (Stempeucel®) was determined by differentiating the cells toward the chondrogenic
lineage and quantifying sulfated glycosaminoglycan (sGAG). The mono-iodoacetate (MIA)-induced preclinical model
of OA has been used to demonstrate pain reduction and cartilage formation. In the clinical study, 60 OA patients
were randomized to receive different doses of cells (25, 50, 75, or 150 million cells) or placebo. Stempeucel® was
administered by intra-articular (IA) injection into the knee joint, followed by 2 ml hyaluronic acid (20 mg). Subjective
evaluations—visual analog scale (VAS) for pain, intermittent and constant osteoarthritis pain (ICOAP), and Western
Ontario and McMaster Universities Osteoarthritis (WOMAC-OA) index—were performed at baseline and at 1, 3, 6,
and 12 months of follow-up. Magnetic resonance imaging of the knee was performed at baseline, and at 6 and
12 months follow-up for cartilage evaluation.
Results: Stempeucel® differentiated into the chondrogenic lineage in vitro with downregulation of Sox9 and
upregulation of Col2A genes. Furthermore, Stempeucel® differentiated into chondrocytes and synthesized a
significant amount of sGAG (30 ± 1.8 μg/μg GAG/DNA). In the preclinical model of OA, Stempeucel® reduced pain
significantly and also repaired damaged articular cartilage in rats. In the clinical study, IA administration of
Stempeucel® was safe, and a trend towards improvement was seen in the 25-million-cell dose group in all
subjective parameters (VAS, ICOAP, andWOMAC-OA scores), although this was not statistically significant when
compared to placebo. Adverse events were predominant in the higher dose groups (50, 75, and 150 million cells).
Knee pain and swelling were the most common adverse events. The whole-organ magnetic resonance imaging
score of the knee did not reveal any difference from baseline and the placebo group.
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Conclusion: Intra-articular administration of Stempeucel® is safe. A twenty-five-million-cell dose may be the most
effective among the doses tested for pain reduction. Clinical studies with a larger patient population are required
to demonstrate a robust therapeutic efficacy of Stempeucel® in OA.
Trial registration: Clinicaltrials.gov NCT01453738. Registered 13 October 2011.
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Osteoarthritis (OA) is a common and debilitating chronic
degenerative disease of large joints, especially the hip and
knee, characterized by a loss of articular cartilage, sub-
chondral sclerosis, and marginal osteophyte formation.
Worldwide, approximately 9.6% of men and 18% of
women aged ≥60 years have symptomatic osteoarthritis
[1]. Current treatment in early-stage OA includes weight
reduction, quadriceps strengthening exercises, non-
steroidal anti-inflammatory drugs, intra-articular (IA)
glucocorticoid injections, viscosupplements, and bracing
[2–4]. Total joint arthroplasty is the mainstay treatment
for end-stage OA of the knee joint, which is often associ-
ated with serious and life-threatening complications in-
cluding increase risk of infection [5].
Currently, cell therapy- and tissue engineering-based
approaches are being used to address the issue of repair
of damaged articular cartilage. This includes autologous
cultured chondrocytes and mesenchymal stromal cells
(MSCs) obtained from various tissues that are used for
transplantation into the cartilage lesion. Autologous
chondrocyte implantation has inherent disadvantages
such as a two-stage surgical procedure (harvesting healthy
cartilage and transplanting culture-expanded chondrocytes
from that sample) that may cause further cartilage damage
and degeneration [6, 7], and chondrocyte dedifferentiation
during culture that might result in fibrocartilage rather than
hyaline cartilage formation [6, 8]. Thus, autologous or allo-
geneic MSCs are rapidly emerging as an investigational
product for cartilage repair [9–11]. The anti-inflammatory
and immunomodulatory properties of MSCs suggest that
these cells can reduce inflammation and pain reduction in
the knee. Concurrently, MSCs may initiate the repair
process of the damaged cartilage by differentiating into
chondrocytes, as well as by inducing proliferation and mat-
uration of the remaining healthy chondrocytes or by indu-
cing differentiation of chondroprogenitors [12]. A whole
host of growth factors, biological modulators, and extracel-
lular matrix proteins produced by MSCs may play a pivotal
role in enhancing neocartilage formation [12].
Several preclinical studies and clinical trials have been
conducted using MSCs which have reported the safety and
therapeutic effect of its administration in patients with OA,
although the majority of these studies have been conducted
as single-dose, single-arm pilot studies [13–15]. Hence,there is a need for randomized, double-blind, con-
trolled clinical trials. We have carried out in vitro
studies to show the differentiation efficiency of adult
human bone marrow-derived, cultured, pooled, allo-
geneic mesenchymal stromal cells (Stempeucel®) into
the chondrogenic lineage and the expression of chon-
drocyte-specific markers. In order to determine if
Stempeucel® is efficacious in a preclinical model, we
have administered these cells intra-articularly into the
knee joints of rats with mono-iodoacetate (MIA)-induced
OA. After completion of these studies, a phase 2 dose-
finding clinical study was initiated to evaluate the safety
(primary endpoint), potential efficacy, and appropriate
dose (secondary endpoints) of IA administration of
Stempeucel® in patients with OA of the knee joint.
Methods
Production and characterization of Stempeucel® and placebo
Stempeucel® is a bone marrow-derived, ex vivo expanded,
pooled, allogeneic human MSC population that has been
characterized previously [16, 17]. The pooled cells were
manufactured in an approved Good Manufacturing Prac-
tice (GMP) facility from bone marrow-derived MSCs
(BMMSCs) of three different healthy volunteers to produce
a working cell bank (WCB). The pooled MSCs from the
WCB were further expanded to manufacture the investiga-
tional medicinal product, Stempeucel®. The cells expressed
all markers characteristic of MSC, were negative for
hematopoietic surface antigens, and also efficiently differ-
entiated into osteocytes, chondrocytes, and adipocytes
in vitro [16]. Two hundred million expanded BMMSCs
were cryopreserved and stored in 15 ml PLASMA-LYTE A
(Baxter, Deerfield, Illinois) containing 5% human
serum albumin and 10% dimethyl sulfoxide (DMSO)
in cryobags (MacoPharma, Mouvaux, France). Placebo
contained 15 ml PLASMA-LYTE A in similar cryo-
bags. The investigational medicinal product (IMP)
specification is given in Table 1.
In vitro studies show differentiation of Stempeucel® to
the chondrogenic lineage and quantification of sulfated
glycosaminoglycan
The chondrogenic differentiation potential of six Stempeucel®
batches was evaluated in monolayer cultures using chondro-
genesis induction medium (catalog no. A10071-01; Gibco).
Table 1 Investigational medicinal product (IMP) specification
S. no Description Specifications
1 Morphology Cells are fibroblastic and spindle-shaped in active growing conditions
Cells are intact and round in shape after trypsin action
2. Cell count 180 to 220 million cells per bag
3. Viability ≥85%
4. Cell phenotype CD 73 >80%
CD105 > 80%
CD 90 > 80%
CD 166 > 80%
CD 34 <5%
CD 45 < 5%
CD 133 < 5%
CD 14 < 5%
CD19 < 5%
HLA-DR < 5%
5. Karyotyping Normal, 46 XY
6. Mycoplasma PCR ELISA Not detected
7. Sterility test Must comply
8. Differentiation assay to adiopocyte, osteocyte, and chondrocyte Confirmation of differentiation
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plates and cultured in DMEM-KO with 10% fetal bovine
serum (FBS) and 2 ng/mL basic fibroblast growth factor
(bFGF) until 80% confluency. The cells were induced to dif-
ferentiation in chondrogenic induction medium (Gibco) for
21 days; the medium was replenished every 3 days and un-
induced cells were harvested at 80% confluency and served as
the corresponding control for background estimation. After
21 days of differentiation, the cells were trypsinized and pel-
leted by centrifugation at 1000 rpm and the chondrogenic dif-
ferentiation was quantified by measuring the amount of
sulfated glycosaminoglycan (sGAG) using a Blyscan kit (cata-
log no. B1000; Bicolor). The final sGAG content was repre-
sented after normalizing with total DNA content estimated
using a Quant-iT Pico green kit (P7589; ThermoFisher, USA).Quantitative RT-PCR for chondrogenic-specific gene markers
Total cellular RNA was isolated using an RNeasy mini
kit (Qiagen) from the undifferentiated and the differenti-
ated BMMSCs for chondroyte lineage (described above).
The RNA samples were treated with RNAse free DNase
I (Ambion), and reverse-transcribed into cDNA using a
high-capacity cDNA reverse transcription kit (Applied
Biosystems) according to the manufacturer’s instruc-
tions. Real-time PCR was carried out using the SYBR
green kit (catalog no. 4309155; Applied Biosystems)
using step one plus (Applied Biosystems). Beta actin
served as the internal control. The sequences for the
gene-specific primers are as follows: Sox9, forward
TTTCCAAGACACAAACATGA, reverse AAAGTC-
CAGTTTCTCGTTGA; Col2A, forward TTTCCCA
GGTCAAGATGGTC, reverse TCACCTGGTTTTC-
CACCTTC. Ct values were normalized to the house-
keeping gene β-actin.Preclinical model of osteoarthritis
Ten-week-old male Wistar rats (n = 80) weighing be-
tween 175 and 285 g were used for the preclinical study.
The experimental protocol was approved by the Institu-
tional Animal Ethics Committee (IAEC), and the experi-
ment was carried out at a CRO animal facility.
Bilateral osteoarthritis was induced in rats (n = 74) by in-
jection of MIA (Sigma-Aldrich, USA) into the knee joints
according to published methods [18–20]. Briefly, the ani-
mals were anesthetized with 3% isoflurane; 1 mg MIA dis-
solved in 50 μl saline was delivered into the articular cavity.
The rats (n= 6) receiving only the saline solution served as
sham control animals (group I) throughout the experiment.
The pain sensitivity of the knee joints was measured before
MIA injection and once every week after MIA injection as
described by Di Cesare et al. [21]. The Pressure Application
Measurement device (PAM; Ugo Basile, Italy) was used to
measure the mechanical pain threshold of the knee joints.
The gram-force (gf) that elicited the limb withdrawal was
recorded. Three weeks after MIA injection, animals display-
ing PAM values that ranged between 272 and 601 gf were
considered to have developed OA and were selected for the
study (n= 60). Prior to performing the experiment described
in this paper, we had conducted a validation study in which
the range of PAM values was evaluated against gross path-
ology and histological evidence of OA in rats (data not
shown). The range of PAM values was selected accordingly
prior to randomizing the animals in the current study. Rats
were divided into four different groups and each group con-
sisted of 15 rats (Table 2). Sham control animals (group I)
showed an average PAM value of 870 ± 138 gf.
Stempeucel® administration in MIA-induced rats
At day 0, animals in both groups 1 (sham control) and
group 2 (vehicle control) received 60 μl vehicle
Table 2 Animal grouping and sacrifice schedule
Group Animals sacrificed (no of rats)*
4 weeks 8 weeks 12 weeks
Group 1 Sham control 2 2 2
Group 2 Vehicle control 3 6 6
Group 3 Hyaluronic acid (HA) 3 6 6
Group 4 Stempeucel® low dose + HA (6 × 105 cells/joint) 3 6 6
Group 5 Stempeucel® high dose + HA (1.3 × 106 cells/joint) 3 6 6
*Number of animals sacrificed at each time point after Stempeucel® administration
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a 27-gauge needle. For group 3 animals, 30 μl hyaluronic
acid (HA; Hyalgan®; Fidia Pharmaceuticals, Italy) was
injected followed by 30 μl vehicle. For group 4 and 5
rats, freshly-thawed Stempeucel® was used after washing
in Plasmalyte A to remove DMSO and resuspending in
Plasmalyte A. Stempeucel® was administered at two dif-
ferent doses: 6 × 105 cells/joint (low dose; human equiva-
lent dose (HED) of 25 million cells) and 1.3 × 106 cells/
joint (high dose; HED of 50 million cells). Both doses
were formulated in 30 μl Plasmalyte A and injected into
group 4 (low-dose group) and group 5 (high-dose group)
animals, respectively. Cell administration was immedi-
ately followed by 30 μl HA injection. In order to reduce
the xenogeneic rejection of cells, cyclosporine A (CsA;
Novartis, Switzerland) was injected subcutaneously into
all the experimental animals at a dose of 10 mg/kg daily
for an initial 1 week starting at day –3 of cell injection,
after which daily CsA administration was continued or-
ally at the same dose until the end of the study. The pain
response was measured at weekly intervals up to week
10. The final measurements were taken at week 12.
Gross and histological evaluation of cartilage repair in
preclinical model
The treatment regimen and the number of animals
sacrificed after BMMSC administration at various time
points are shown in Table 2. Rats from all the groups
were sacrificed at 4, 8, and 12 weeks after vehicle/HA/
Stempeucel® administration. The knee joints were dis-
sected and the cartilage surface was visualized macro-
scopically on the exposed joints, and the distal femur
from the right joints was dissected and processed for
histological analysis.
All joint specimens were fixed in 10% formalin buffer
and then decalcified in 10% EDTA (RFCL, India) for
2 weeks; the decalcification solution was changed twice in
a week. The joints were embedded in paraffin; serial sagit-
tal sections (5-μm thick) were prepared and stained with
hematoxylin and eosin (H&E) and Safranin-O fast green
staining for proteoglycan visualization and estimation
[22]. The severity of articular damage was evaluated using
the Osteoarthritis Research Society International (OARSI)grading system [23, 24] on the H&E-stained sections. The
binding intensity of Safranin-O to the sGAG was quanti-
fied using imageJ software [25]. The region of interest
(ROI) around the cartilage area (n = 3 per section) was se-
lected, and the intensity of red (R), green (G), and blue (B)
were measured and the proportion of red staining was cal-
culated using the equation r = R/ (R2 + G2 + B2)1/2 where,
R is the intensity of red and 'r' refers to the intensity of the
red fraction with respect to other primary colors [26].
The sections were graded and quantified by an independ-
ent observer blinded to the treatment groups.
Clinical study design and enrollment criteria
This was a randomized, double-blind, multicentric,
placebo-controlled, phase II study assessing the safety and
efficacy of IA Stempeucel® in patients with OA of knee.
The study was conducted in accordance with the Good
Clinical Practice (GCP) guidelines as issued by the Inter-
national Conference on Harmonization (ICH/135/95, July
2002), Schedule Y of the Drugs and Cosmetics Rules,
1945, Ethical guidelines for biomedical research on human
participants prepared by the Indian Council of Medical
Research in 2006 and the Declaration of Helsinki (64th
WMA General Assembly, Fortaleza, Brazil, October
2013). Approval was obtained from the Central Drugs
Standard Control Organization (Indian FDA) and the in-
stitutional ethics committees of the five participating hos-
pitals. The study was registered in the National Institute
of Health registry of clinical trials (https://clinicaltrials.-
gov/ct2/show/NCT01453738). An independent data safety
monitoring board was formed comprising of drug safety
physicians and an expert in the therapeutic area to moni-
tor the safety data at predefined intervals during the pro-
gress of the study. The study was conducted from
November 2011 to November 2013. Written informed
consent was obtained from all participants before screen-
ing. Of the 82 patients screened, 62 patients were random-
ized to the study from five centers. Two patients dropped
out from the study after randomization but before IMP
administration; thus 60 patients received the IMP. Four
dose levels were studied in this trial: 25, 50, 75, and 150
million cells (25 M, 50 M, 75 M, and 150 M, respectively).
At each dose level, 15 patients were randomized into two
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computer generated randomization. Thus, 10 subjects re-
ceived Stempeucel® and 5 subjects received placebo at
each dose level (Fig. 1). As this was the first study of IA
administration of Stempeucel® in OA patients, no formal
sample size calculation was performed. Eligibility criteria
of the patients in the trial are given in Table 3.
Preparation of IMP at the clinical trial sites
Block randomization (block size 5) was performed cen-
trally by a biostatistician using PROC PLAN in SAS.
The IMP (Stempeucel® or placebo) was shipped in a
cryoshipper (temperature –185 to –196 °C) to clinical
trial sites whenever each patient was eligible for the
study. Preparation of IMP for injection was performed
under a validated biosafety cabinet by a trained person
independent of the investigator’s team. A cryobag con-
taining IMP was thawed at 37 °C in a water bath. The
cell suspension was diluted to 100 ml using PLASMA-
LYTE A using two 50-ml centrifuge tubes. The cell pel-
let was resuspended in 2 ml PLASMA-LYTE A (for the
25- and 50-million-cell dose groups) and in 4 ml
PLASMA-LYTE A (for the 75- and 150-million-cell dose
groups) based on the viable cell count and was loaded to
a blinded syringe. For the placebo preparation, a similarFig. 1 CONSORT flow chart showing the number of patients randomized, fol
intention to treatamount of PLASMA-LYTE A was loaded to a blinded
syringe. The IMP (Stempeucel® or placebo) was pre-
sented to the investigators in a blinded syringe (using
semitransparent tape) in a temperature-controlled trans-
port box at 2–8 °C. It was not possible to distinguish be-
tween Stempeucel® and placebo upon visual inspection
of the blinded syringes.Injection protocol for the clinical study
Pre-medication (hydrocortisone 100 mg IV and phenira-
mine maleate 45.5 mg IV) was administered 15–30 min
before administration of the IMP to prevent the possibil-
ity of a potential anaphylactic reaction to the allogeneic
cells. The IA injections were performed by qualified and
experienced investigators (either orthopedician or
rheumatologist) using a 2.0-inch (5.1-cm) 20-gauge nee-
dle as a lateral midpatellar injection (an injection into
the patellofemoral joint). IMP injection was followed by
injection of 2 ml hyaluronic acid (20 mg; Hyalgan, Fidia
Farmaceutici S.p.A., Italy). Patients were hospitalized for
the procedure, and were monitored for 24 h after the
injection. Patients were discharged after inspection of
the target joint, a general physical examination, and vital
signs evaluation.lowed-up, and analyzed. M million cells, Cell Stempeucel®, mITT modified
Table 3 Subject eligibility criteria
Inclusion criteria
1. Males or females in the age range 40–70 years (both inclusive)
2. Radiographic evidence of grade 2 to 3 osteoarthritis (OA) based on
the Kellgren and Lawrence radiographic entry criteria*
3. History of primary idiopathic OA of the knee characterized by pain
which required intake of analgesics
4. Self-reported difficulty in at least one of the following activities
attributed to knee pain: lifting and carrying groceries, walking 400
meters, getting in and out of a chair, or going up and down stairs
5. Patients who had been on stable medication, including non-steroidal
anti-inflammatory drugs (NSAIDs)/opioid or opiate analgesics, for the
past 3 months
6. Female patients of childbearing age who agreed to use accepted
methods of contraception during the course of the study
7. Ability to provide written informed consent
Exclusion criteria
1. Prior or ongoing medical conditions (e.g., concomitant illness,
psychiatric condition, alcoholism, drug abuse), medical history, physical
findings, electrocardiogram (ECG) findings, or laboratory abnormality
that, in the investigator’s opinion, could adversely affect the safety of the
subject, makes it unlikely that the course of treatment or follow-up
would be completed or could impair the assessment of study results
2. History of surgery or major trauma to the study joint
3. Arthroscopy on the study joint in the previous 12 months
4. Signs of active study joint inflammation including redness, warmth,
and/or, if qualifying with OA of the knee, a large, bulging effusion of
the study knee joint with the loss of normal contour of the joint at
the screening visit or at the baseline examination
5. Patients who received intra-articular steroids or hyaluronan within the
last 3 months
6. Infections in or around the knee
7. Patients awaiting a replacement knee or hip joint
8. Patients with other conditions that caused pain
9. Patients with deformity of the knee joint
10. Significantly incapacitated or disabled and would be categorized as
ACR Functional Class IV (largely or wholly incapacitated) or unable to
walk without assistive devices
11. Patients with other known rheumatic or inflammatory disease such
as rheumatoid arthritis
12. Other pathologic lesions on X-rays of knee
13. Positive hepatitis B surface antigen, hepatitis C antibody test, anti-HIV
antibody test, or Rapid Plasma Reagin (RPR)
14. History of bleeding disorders
15. Known hypersensitivity to hyaluronan or animal sera
16. For women of child-bearing potential: positive pregnancy test or
lactating (females who were planning pregnancy within the next
year were excluded)
*If both knees of a patient were eligible to be included in the study, the knee
to be included was as per investigator judgment
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Patients were followed up at 1 week, and 1, 3, and
6 months after injection of IMP. The clinical data were
unblinded after 6 months and patients were further
followed-up for both safety and efficacy until 12 months
after the injection. Safety assessments included monitor-
ing of all adverse events (AEs), assessment of electrocar-
diogram (ECG) parameters, hematological (complete
blood count including erythrocyte sedimentation rate)
and biochemical (liver function tests, kidney function
tests, and lipid profile) values, physical examination, and
vital signs measurements. Adverse events were captured
by interviewing the subjects and laboratory data evalua-
tions during the visits. The efficacy endpoints includedimprovement in pain from OA graded on a visual analog
scale (VAS) from 0 to 10 (0 = no pain; 10 = worst pain);
also, the Western Ontario and McMaster Universities
Osteoarthritis (WOMAC-OA) index (total score, pain,
stiffness, and physical function scores) and intermittent
and constant osteoarthritis pain (ICOAP) was used (con-
stant and intermittent pain score) to evaluate pain and
function of the joint. X-ray of the knee was carried out
at baseline, and at 3 and 6 months follow-up. Magnetic
resonance imaging (MRI) of the knee was carried out at
baseline, and at 6 and 12 months follow-up. MRI of the
knee was performed using a 1.5-T whole body scanner
and a circumferential eight-channel knee coil. Proton
density T2-weighted sequences were captured: sagittal
intermediate, axial intermediate, and coronal intermedi-
ate for assessing osteophytes and cartilage (for scoring
cartilage signal and morphology, marginal osteophytes,
subarticular bone marrow abnormality, subarticular cysts,
and subarticular bone attrition); sagittal PD FS for asses-
sing menisci and cruciate ligaments (for scoring of ACL,
PCL, medial, and lateral menisci); and sagittal 3D
FIESTA-C for assessing cartilage surface and superficial
erosions (for scoring cartilage signal and morphology).
Images were scored to assess the whole-organ magnetic
resonance imaging score (WORMS) by two experienced
radiologists using combined reads. In case of non-
concurrence, advice was taken from a third independent
radiologist whose report was considered final. WORMS
scoring used in this study was modified for calculation of
total WORMS score. The parameters included were ar-
ticular surface features which include cartilage signal and
morphology, subarticular bone marrow abnormality, sub-
articular cysts, subarticular bone attrition, and marginal
osteophytes. They were scored for all 14 compartments of
the knee joint. The compartment totals were added to ob-
tain the overall knee joint score [27].
Statistical analysis
Preclinical data
GraphPad Prism software was used to calculate the stat-
istical significance of all preclinical experimental data.
The data are expressed as the mean ± SEM. Quantitative
RT-PCR data analysis was performed using Student’s
t test. Pain threshold differences between various treat-
ment groups and the Safranin-O quantification were ex-
amined for statistical significance using two-way analysis
of variance followed by a Bonferroni post-hoc test. The
OARSI grade analysis was performed using one-way ana-
lysis followed by Kruskal–Wallis test. P < 0.05 denoted the
presence of a significant difference between groups.
Clinical trial data
The SAS package (SAS® Institute Inc., USA, version 9.2)
was used for statistical evaluation. For analysis purpose,
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(25 M, 50 M, 75 M, and 150 M cell dose), and two pla-
cebo groups. Patients who received placebo in 25 M and
50 M dose levels were grouped into one placebo group
(both received the IMP in 2 ml PLASMA-LYTE A; P1)
and those who received placebo corresponding to the
75 M and 150 M dose groups (both received the IMP in
4 ml PLASMA-LYTE A) were grouped into another
group (P2). Thus, there were four treatment groups and
two placebo groups forming a total of six groups. The
treatment groups 25 M and 50 M were compared with
P1 (the three groups collectively called cohort 1) and
treatment groups 75 M and 150 M were compared with
P2 (the three groups collectively called cohort 2). AEs
were coded by the Medical Dictionary for Regulatory Ac-
tivities (MedDRA) primary system organ class (SOC) and
preferred term (PT). AEs were summarized descriptively
by total number of AE(s) and compared between the
six study groups. Continuous variables are presented
as mean ± SD. The data distribution was visually ex-
amined for normality before applying the statistical
tool for analysis. Comparisons among groups were
conducted using Kruskal–Wallis test, with alpha set
at 0.05 for significance.
Results
Differentiation efficiency of Stempeucel® into
chondrogenic lineage in vitro
We evaluated the chondrogenic differentiation potential
of Stempeucel® batches in monolayer cultures. The extent
of differentiation was also assessed by mRNA expression of
Sox9 and Col2A. We observed a significant downregulation
of Sox9, which is an early inducer of chondrogenesis in the
differentiated cells compared to the control (P < 0.02, n = 6),
and upregulation of Col2A, the gene that encodes for type
2 collagen, a major cartilage matrix protein and a mature
chondrocyte marker (Fig. 2a and b). Chondrogenic differen-
tiation of BMMSCs was quantified by measuring the amal-
gamation of sGAG which is known to play a central role in
cartilage homeostasis [28]. All six batches of Stempeucel®
differentiated to chondrocytes and synthesized significant
amount of sGAG (30 ± 1.8 μg/μg GAG/DNA) compared to
that produced by the undifferentiated cells (12.07 ± 5.6 μg/
μg GAG/DNA; P < 0.001, n = 6) (Fig. 2c). These data sug-
gest that the pooled BMMSC samples efficiently differenti-
ated into the chondrogenic lineage, confirming the
presence of mature chondrocytes after differentiation.
Intra-articular administration of Stempeucel® ameliorates
OA-induced joint pain in a preclinical model
The MIA-induced OA model was the first validated pain
model of OA used to evaluate the analgesic and anti-
inflammatory properties of therapeutic agents [20]. In our
study, the mechanical pain threshold was measuredweekly by PAM test. Pain threshold values from various
time points are shown in Fig. 3a. Analysis of PAM scores
indicates that animals treated with both low and high
doses of Stempeucel® showed improvement in pain
threshold from week 2 onwards as compared to vehicle or
HA-treated animals and continued to improve until
8 weeks after cell injection. While the pain improvement
appeared to reach saturation by 8 weeks with the low dose
of cells, it continued to improve until 12 weeks in the ani-
mals that received a high dose of Stempeucel® (Fig. 3a).
Animals treated with HA alone showed some improve-
ment in pain threshold at the initial time period (week 3);
however, this improvement was not found to be consist-
ent. When comparing the PAM scores between the HA-
and Stempeucel®-treated groups, animals treated with the
high dose of cells exhibited a significant pain-reduction ef-
fect at week 4 (P < 0.001), week 8 (P < 0.001) and week 12
(P < 0.05), whereas the low-dose group showed a signifi-
cant effect at week 4 (P < 0.05) and week 8 (P < 0.001), but
not at week 12. These results clearly demonstrate that
intra-articularly injected Stempeucel® is able to reduce the
pain significantly in the MIA-induced OA rat model.
Cartilage repair induced by Stempeucel® administration
in a preclinical model
Macroscopic evaluation of articular cartilage was per-
formed in rats at 4, 8, and 12 weeks after cell injection.
Varying degrees of cartilage damage were observed in
animals injected with MIA and subsequently adminis-
tered with vehicle. These degenerative changes include
cartilage fibrillation, erosion, and osteophyte formation
(data not shown). The degree of cartilage damage was
progressively reduced with both low and high doses of
Stempeucel® + HA treatment, while only marginal
change was noticed in a few HA-treated animals.
Based on H&E staining of the cartilage tissue, we
scored the femoral condyle section of rats using the
OARSI grading system. As expected, sham control ani-
mals showed a normal histological appearance of the
cartilage throughout the study (Fig. 3b, panels a, f, and k
for weeks 4, 8, and 12, respectively). In the vehicle-
treated animals, the OA joints showed fibrillation, and
appreciable loss of chondrocytes was observed at both
weeks 4 and 8 (Fig. 3b, panels b and g). By week 12, the
cartilage damage was found to be severe and the hyaline
tissue was replaced with fibrocartilage (Fig. 3b, panel l).
The HA-treated animals showed marginal improvement
in cartilage architecture (Fig. 3b, panels c, h, and m). In
contrast, animals receiving both low and high doses of
Stempeucel® showed almost intact cartilage with a larger
number of chondrocytes (Fig. 3b, panels d, i, and n for a
low dose of cells and panels e, j, and o for a high dose of
cells). The calculated OARSI grades of the different
treatment groups were compared at week 12. Although,
Fig. 2 Quantification of gene expression and sGAG. Quantitative mRNA expression of a SOX9 and b Col2A in the control (white bar) and
chondrogenically differentiated Stempeucel® (black bar) by real-time PCR analysis (n = 6). c Sulfated glycosaminoglycan (sGAG) content in the control
(white bar) and chondrogenically differentiated Stempeucel® (black bar) by DMMB dye-binding assay. The sGAG values were normalized to the DNA
content in the control and chondrogenically differentiated Stempeucel® (n = 6). Results are represented as mean with SEM
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ment, a statistically significant reduction in OARSI grade
was observed only in the high-dose Stempeucel®-treated
animals (P < 0.05) in comparison to animals in the vehicle
group. The Safranin-O stained area of the cartilage was
greater in both the cell-treated groups (Fig. 4a, panels d, i,
and n for the low dose and panels e, j, and o for the high
dose). It is important to note that the intensity of Safranin-
O staining increased progressively with both doses of
Stempeucel®. In fact, at week 12, Safranin-O staining inten-
sity was found to be comparable between the high- and
low-cell dose animals and sham controls (Fig. 4a). In
comparison to the HA- and vehicle-treated groups, sGAG
intensity was found to be significantly higher in Stempeu-
cel®-treated and in sham control animals at week 12
(Fig. 4b). These findings suggest that intra-articularly
injected Stempeucel® + HA repaired MIA-induced articular
cartilage damage in rats with OA of the knee joint.Clinical study
Demographics and baseline characteristics of patients
The demographics and other baseline characteristics of
the enrolled patients are presented in Table 4. All six
groups were mostly comparable in terms of baseline
characteristics. Sixty patients were included in the modi-
fied intention to treat analysis (mITT) group. There was
no premature unblinding of any patient. The patients’
age, sex, weight, height, and body mass index (BMI)
were balanced across groups. High scores for VAS,
WOMAC, and ICOAP suggest that these patients had
severe pain and were balanced across all groups.
Procedural safety
All patients tolerated the procedure well in cohort 1 (25 M,
50 M, and P1) and cohort 2 (75 M, 150 M, and P2). Ten
patients (1 in 50 M, 6 in 75 M, and 3 in 150 M dose
groups) experienced pain and swelling at the injection site.
Fig. 3 Effect of intra-articular injection of Stempeucel® on pain reduction and cartilage repair in an osteoarthritic rat model. a The effect of Stempeucel® on
pain reduction at week 0 (before cell injection), and at weeks 4, 8, and 12 after cell injection. Data are presented as mean ± SEM. *P< 0.05, ***P< 0.001
versus hyaluronic acid (HA)-treated group. b Photomicrographs of representative joint sections of femoral condyle stained with H&E at 4 (a–e), 8 (f–j), and
12 weeks (k–o) after Stempeucel® treatment. Osteoarthritic changes, such as loss of chondrocytes (*), loss of cartilage (vertical arrow), and
fibrillation (thin arrow) are evident in vehicle-treated and HA-treated joints. Proliferation of chondrocytes (thick arrow), regeneration, and
repair of cartilage tissue was evident in Stempeucel®-treated groups. Scale bars = 100 μm, magnification 10×. H high dose of Stempeucel®,
L Low dose of Stempeucel®, MIA mono-iodoacetate, ns not significant
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related to the IMP, and recovered upon conservative ther-
apy. Among the 10 patients, one subject (150 M dose
group) had IMP-related synovial effusion requiring
hospitalization for one additional day of observation, thus
meeting the criteria of a serious adverse event (SAE). Other
SAEs in the study were determined to be unrelated to the
IMP and were as follows: hysterectomy for menorrhagia in
one subject in the 25 M group, suture-related complication
and varicose vein in one subject in the P1 group, and
hemorrhoidal hemorrhage and umbilical hernia, respect-
ively, in one subject each in the P2 group.Overall evaluation of adverse events
A total of 97 AEs were reported in 40 subjects (Table 5).
The distribution of AEs in the different dose groups was
as follows: 24 (25 M), 13 (50 M), 21 (P1), 17 (75 M), 11
(150 M), and 11 (P2). No patient died or was withdrawn
from the study due to an AE. Most of the AEs were mild
to moderate in severity. One severe AE was reported in
each of 25 M (dyslipidemia), 50 M (anemia), 150 M
(muscle hemorrhage), and P2 (umbilical hernia) groups.
Physical examination and vital signs data were unre-
markable after the injection. In cohort 1, most of the
AEs observed in the study were related to the SOC
Fig. 4 Histological evaluation of Safranin-O stained joint sections. a Photomicrographs of representative joint specimens of femoral
condyle stained with Safranin-O at 4 (a–e), 8 (f–j), and 12 weeks (k–o) after Stempeucel® treatment. Loss of articular surface, roughening
of cartilage and reduced staining of Safranin-O (thin arrow) were observed in vehicle- and HA-treated joints. Strongly stained Safranin-O-
positive cartilage (thick arrow) with increased numbers of chondrocytes was seen in the Stempeucel®-treated groups. Scale bars = 100 μm,
magnification 10×. b Sulfated glycosaminoglycan (GAG) fraction intensity was measured from histological images of Safranin-O-stained sections at
weeks 4, 8, and 12. The intensity of Safranin-O staining is represented graphically, and the data are represented as mean ± SEM. At 12 weeks, the
Stempeucel®-treated groups (both low (L) and high (H) dose) showed a significant improvement in the sGAG content compared to the
disease control (mono-iodoacetate; MIA) and hyaluronic acid (HA)-treated groups. *P < 0.05, *** P < 0.001. ns not significant
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most common AE was arthralgia. In cohort 2, most of
the AE(s) observed in the study were related to the SOC
(general disorders and administration site conditions).
The most common AEs in the 75 M group were injec-
tion site pain and arthralgia. Three events of arthralgia
were experienced by two subjects (one subject had two
episodes of arthralgia due to OA) and four events of in-
jection site joint pain were experienced by four subjects
in the 75 M dose group. One event of hypersensitivity to
IMP (joint swelling) was experienced by a subject in the
75 M dose group. Three events of hypersensitivity to
IMP (joint swelling) were experienced by three subjects
in the 150 M group. All events of joint pain and swelling
recovered completely upon symptomatic treatment.Hematology, serum chemistry, serology, urine analyses,
and ECG evaluation did not reveal any significant
abnormalities.Efficacy results
VAS scores decreased over the study period for all the
treatment groups except for patients in the 150 M
group. The maximum reduction in the VAS score was
seen in the 25 M group at 12 months compared to the
other groups of patients (40.3 ± 17.3, 30.3 ± 31.0, and
21.3 ± 28.3 cm in 25 M, 50 M, and P1, respectively; P =
0.3833). VAS decreased by 67.4% in the 25 M group
compared to 41.4% and 36.0% in the 50 M group and
P1, respectively (P = 0.0587) (Fig. 5).
Table 4 Summary of Demographic Characteristics at Baseline
Cohort 1 Cohort 2
Parameter 25 M (n = 10) 50 M (n = 10) P1 (n = 10) P value 75 M (n = 10) 150 M (n = 10) P2 (n = 10) P value
Age (years) 58.10 ± 8.23 57.30 ± 9.45 54.90 ± 8.27 0.73 55.00 ± 6.72 54.00 ± 6.73 56.70 ± 5.19 0.6
Female (n) 7 8 10 NA 8 5 7 NA
Male (n) 3 2 0 NA 2 5 3 NA
Height (cm) 156.85 ± 9.64 157.30 ± 12.23 152.25 ± 9.72 0.39 158.40 ± 8.86 158.88 ± 9.30 159.70 ± 10.67 0.9
Weight (kg) 73.10 ± 15.86 69.00 ± 14.62 66.10 ± 7.67 0.45 71.30 ± 9.09 66.00 ± 9.13 66.90 ± 8.57 0.39
BMI (kg/m2) 29.73 ± 6.09 27.74 ± 4.16 28.84 ± 4.91 0.76 28.38 ± 2.38 26.33 ± 4.48 26.40 ± 3.99 0.3
WOMAC total 1315.8 ± 444.8 1498.4 ± 407.4 1239.6 ± 472.2 0.28 1470.6 ± 471.0 1388.1 ± 508.8 1382.0 ± 324.7 0.9
ICOAP total 45.7 ± 19.2 59.3 ± 21.7 49.3 ± 18.7 0.38 58.4 ± 20.7 46.4 ± 22.0 54.8 ± 17.8 0.54
VAS 60.9 ± 19.7 73.7 ± 15.2 61.0 ± 23.8 0.24 57.4 ± 29.0 46.6 ± 23.6 65.3 ± 12.2 0.11
WORMS total score 67.0 ± 19.8 78.8 ± 40.9 76.5 ± 23.5 0.65 71.3 ± 21.4 62.0 ± 17.9 70.8 ± 14.7 0.48
Kellgren and Lawrence Grade 2 (n) 4 1 3 NA 1 3 2 NA
Kellgren and Lawrence Grade 3 (n) 6 9 7 NA 9 7 8 NA
Values are shown as mean ± SD unless indicated otherwise
25 M, 50 M, 75 M, 150 M = 25, 50, 75, and 150 million cells, respectively
P1, P2 = placebo 1 and placebo 2, respectively
BMI body mass index, ICOAP intermittent and constant osteoarthritis pain, NA statistical comparisons for these groups have not been conducted due to too few
samples, VAS visual analog scale, WOMAC Western Ontario and McMaster Universities
Table 5 Summary of adverse events
Cohort 1 Cohort 2
System organ class 25 M (n = 10) 50 M (n = 10) P1 (n = 10) 75 M (n = 10) 150 M (n = 10) P2 (n = 10)
Any adverse event 24 (7) 13 (7) 21 (7) 17 (7) 11 (6) 11 (6)
Blood and lymphatic system disorders 0 1 (1) 1 (1) 0 0 0
Endocrine disorders 0 0 0 1 (1) 0 0
Eye disorders 0 1 (1) 0 0 0 0
Gastrointestinal disorders 1 (1) 0 2 (2) 1 (1) 0 3 (3)
General disorders and administration site conditions 2 (1) 4 (2) 0 9 (6) 4 (3) 0
Infections and infestations 3 (3) 1 (1) 4 (3) 0 1 (1) 1 (1)
Injury, poisoning, and procedural complications 0 0 1 (1) 2 (1) 3 (3) 0
Investigations 2 (2) 1 (1) 1 (1) 0 1 (1) 2 (2)
Metabolism and nutrition disorders 4 (3) 0 3 (3) 0 0 1 (1)
Musculoskeletal and connective tissue disorders 6 (3) 3 (3) 5 (4) 4 (2) 2 (2) 3 (2)
Nervous system disorders 1 (1) 0 1 (1) 0 0 0
Renal and urinary disorders 0 1 (1) 0 0 0 0
Reproductive system and breast disorders 1 (1) 0 0 0 0 0
Respiratory, thoracic, and mediastinal disorders 0 0 0 0 0 1 (1)
Skin and subcutaneous tissue disorders 1 (1) 0 1 (1) 0 0 0
Surgical and medical procedures 2 (1) 0 0 0 0 0
Vascular disorders 1 (1) 1 (1) 2 (1) 0 0 0
Values are shown as number of events (number of patients)
25 M, 50 M, 75 M, 150 M = 25, 50, 75, and 150 million cells, respectively
P1, P2 = placebo 1 and placebo 2, respectively
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the study period for all the treatment groups. The max-
imum reduction in the WOMAC composite score was
seen in the 25 M group at 12 months compared to the
other groups (717.8 ± 503.8, 359.9 ± 786.4, and 233.8 ±
641.9 in the 25 M, 50 M, and P1 groups, respectively;
P = 0.2651). The WOMAC composite index decreased
by an mean of 64.8% in the 25 M patients compared
to 14.4% and 49.3% in the 50 M and P1, respectively
(P = 0.1793). A similar trend was observed in all the
WOMAC subscores (WOMAC pain reduced by 145.1 ±
105.2, 74.1 ± 167.2, and 57.4 ± 151.3 (P = 0.3484);
WOMAC stiffness reduced by 69.6 ± 44.7, 4.5 ± 87.2, and
25.8 ± 53.4 (P = 0.0324); and WOMAC physical function
reduced by 503.1 ± 375.1, 290.3 ± 559.2, and 150.6 ± 457.8
(P = 0.2939) in the 25 M, 50 M, and P1 groups, respect-
ively) (Fig. 6).
ICOAP total scores decreased over the study period
for all the treatment groups, except the 150 M group.
The maximum reduction in the ICOAP total score was
seen in the 25 M group at 12 months (21.4 ± 21.2,
12.3 ± 27.4, and 7.5 ± 27.1 in the 25 M, 50 M, and P1
groups, respectively; P = 0.5271) (Fig. 7). ICOAP total
decreased by 34.6% in the 25 M group compared to
29.0% and 22.2% in the 50 M and P1 groups, respectively
(P = 0.3844). A similar trend was seen in ICOAP subscores
(constant pain reduced by 26.5 ± 25.3, 20.5 ± 30.2, and
12 ± 31.8 (P = 0.6140); intermittent pain reduced by
17.1 ± 28.4, 5.4 ± 33.1, and 3.8 ± 26.3 (P = 0.6215) in
the 25 M, 50 M, and P1 groups, respectively).
Thus, overall the patients in the 25 M group consist-
ently showed pain reduction in all subjective parameters
measured in the study. Due to the small sample size,
none of the efficacy parameters were statistically signifi-
cant as the study was not powered for establishing effi-
cacy. There were no clinically meaningful changes in the
X-ray parameters at follow-up visits compared to baseline
(data not presented). In the MRI evaluation, overall,Fig. 5 Visual analog scale values. Data are presented as mean ± SD. 1 M, 3
C2 cohort 2, M million cells, P placebo, VAS visual analog scalethere was no perceptible change in WORMS score in-
cluding cartilage signal and morphology from baseline
to follow-up visits in any of the groups of patients
(Table 6).
Discussion
The propensity of MSCs to differentiate into chondro-
cytes in vitro [29] and their ability to repair articular car-
tilage has been shown in various preclinical models of
OA [30–32]. In several studies, MSCs were prepared
and injected with sodium hyaluronan to increase the
engraftment and chondrogenic activity [30, 33]. In the
present study, the efficacy of Stempeucel® was evaluated
in a well-validated animal model of OA that was induced
by MIA injection into the knee joints. Both low and high
doses of Stempeucel® + HA treatment showed significant
improvement in the pain threshold from week 2 on-
wards when compared to animals treated only with HA;
treatment with only HA provided a short-term benefit
on pain reduction, which corroborates with an earlier
publication [34]. We did not observe a significant differ-
ence between the two Stempeucel® treatment groups of
animals (low and high dose) on pain reduction. How-
ever, it is important to note that the pain reduction in
the high-dose animals continued to improve until the
end of the study (12 weeks). Although the exact mech-
anism of action of MSCs on pain reduction is not
known, anti-inflammatory activity has been attributed to
this effect. To date, some studies have demonstrated the
role of MSCs on OA-induced pain behavior [35–37].
Van Buul et al. reported improvement of weight-bearing
joints of the affected limb after intra-articular applica-
tion of both rat and human BMMSCs in MIA-induced
OA rats [37]. However, unlike the results presented in
this study, the authors did not observe cartilage regener-
ation. Furthermore, in several animal studies, it has been
shown that the increased levels of pro-inflammatory





Fig. 6 WOMAC results. WOMAC a, b composite, c, d pain, e, f stiffness, and g, h physical function (PF) results are shown for cohorts 1 (a, c, e
and g) and 2 (b, d, f, and h). Data are presented as mean ± SD. 1 M, 3 M, 6 M, and 12 M = 1, 3, 6, and 12 months, respectively; C1 cohort 1, C2
cohort 2, M million cells, P placebo, WOMAC Western Ontario and McMaster Universities
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ant role in attenuating the inflammation-induced pain
by secreting a wide range of anti-inflammatory cytokines
and analgesic peptides [38], and Stempeucel® might have
also contributed to pain reduction through a similar
mechanism.
We also demonstrated that the pooled BMMSC popula-
tion are efficient in differentiating into chondrocytes
in vitro, and secrete a significant amount of sGAG
(Fig. 2c). When these cells were administered intra-
articularly into OA-affected joints, we observed a progres-
sive increase in proteoglycan staining. The improvement
in cartilage repair was observed both macroscopically and
microscopically. The sGAG intensity data revealed that
the total proteoglycan content was significantly higher in
both the cell + HA treated groups compared to animalstreated only with HA. One of the short comings of the
preclinical results is that we did not determine the thera-
peutic effect of BMMSCs without HA. However, based on
the published data it appears that administration of MSCs
in combination with HA provided better therapeutic
benefit than either HA or MSC treatment alone in an ex-
perimental animal model of OA [30]. The concomitant re-
duction in MIA-induced pain followed by an increase in
cartilage regeneration observed in this study suggests that
human bioactive factors synthesized by BMMSCs may be
responsible for both the reduction in inflammation and
promotion of endogenous cartilage regeneration via a
paracrine mechanism [12].
This clinical study met its predefined endpoint of
safety of intra-articular administration of Stempeucel® in




Fig. 7 ICOAP results. ICOAP a, b total, c, d constant pain, and e, f intermittent pain results are shown for cohorts 1 (a, c, and e) and 2 (b, d, and
f). Data are presented as mean ± SD. 1 M, 3 M, 6 M, and 12 M = 1, 3, 6, and 12 months, respectively; C1 cohort 1, C2 cohort 2, ICOAP intermittent
and constant osteoarthritis pain, M million cells, P placebo
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in patients randomized to the higher dose groups (75 M
and 150 M) and they resolved completely upon symp-
tomatic treatment. There was no evidence of ectopic tis-
sue or tumor formation locally at 1-year follow-up.
Hematological, biochemical, and serological parameters
were comparable in both the cell and placebo arm in all
groups of patients. Limited joint space, higher dose, and
volume of injection (6 ml) may be the reason for in-
creased joint swelling and pain seen in cohort 2 (75 M
and 150 M). Furthermore, it can be assumed that a pro-
portion of the cells injected into the joint space have not
survived and this phenomenon was more pronounced
with higher cell doses. Probably, such non-viable cells
produce an inflammatory reaction causing pain andTable 6 WORMS scoring of MRI of the knee at each visit
WORMS 25 M 50 M P1 P va
Baseline 67.0 (19.8) 78.8 (40.9) 76.5 (23.5) –
6 months 67.5 (20.5) 77.9 (41.2) 74.9 (22.4) 0.55
12 months 66.1 (19.2) 78.0 (41.1) 74.9 (22.5) 0.53
Values are shown as mean (SD)
The range of WORMS score used in this study was 0–314
25 M, 50 M, 75 M, 150 M = 25, 50, 75, 150 million cells, respectively
P1, P2 = Placebo 1 and 2, respectively
MRI magnetic resonance imaging, WORMS whole-organ magnetic resonance imaginswelling, as reported earlier [39]. The frequency of these
complications was similar to a report from another study
using culture-expanded bone marrow-derived MSCs
[40]. In another study using allogeneic non-HLA
matched BMMSCs in two different doses (50 and 150
million cells) which were pre-mixed with hyaluronic acid
(5 ml) and administered in partial medial meniscectomy
patients [10], the adverse events were similar to those
seen in our study, with the most frequently reported AE
by system organ class being musculoskeletal and con-
nective tissue disorders [10]; however, the adverse events
did not differ between the two doses tested. Recently,
Vega et al. have conducted a study using IA injection of
allogeneic BMMSCs (40 million cells suspended in 8 ml
of Ringer-Lactate) in OA of the knee joint [11]. Post-lue 75 M 150 M P2 P value
71.3 (21.4) 62.0 (17.9) 70.8 (14.7) –
21 71.4 (20.9) 62.0 (17.7) 69.9 (14.3) 0.7360
10 67.0 (20.9) 60.6 (15.7) 72.3 (15.2) 0.0609
g score
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tients in both the experimental and control groups. The
pain responded to analgesics and improved within 1 to
6 days. Hence, pain and local swelling may be the most
common post-injection complication in patients after IA
injection of MSCs which responds within a few days of
symptomatic treatment.
One of the most important factors influencing the
clinical outcome of a study is to determine the optimal
treatment dose. In this study, patients in the low-dose
group (25 million cells) showed improved outcomes in
the pain measurement scores, whereas those in the
higher dose groups did not. The VAS and WOMAC
composite index scores decreased by 64% and 64.4% in
the 25-million-cell arm as compared to 36% and 49.3%
in the active controls with HA, respectively, at 12 months
follow-up. In a proof of concept study, three doses of au-
tologous adipose tissue-derived MSCs (AD-MSCs) were
used: 10 million, 50 million, and 100 million cells. The
WOMAC score improved at 6 months follow-up in the
high-dose group [14]. In another study using allogeneic
BMMSCs at a dose of 40 million cells, improvement in
pain, disability, quality of life, and cartilage quality by
MRI was noted in the cell-treated group [11]. Several
reasons are hypothesized for this effect in the low-dose
group of patients as observed in this study. Firstly, a
dose of 25 M cells may be optimum with the volume of
hyaluronic acid (2 ml) used in the study as a supporting
matrix. Secondly, the 25-million-cell dose maybe optimal
for the limited IA space in the knee joint. Thirdly, doses
higher than 25 million might cause cell aggregation due
to a high cell concentration or insufficient space in the
knee joint and subsequently cause cell death. Fourthly,
the 25-million-cell dose may be lying in the upper range
of the efficacy dose since numerous studies reports that
doses in the range of 10 to 25 million BMSCs may be ef-
ficacious in OA of the knee joint [15, 41–45]. Finally,
higher doses of MSCs may activate the MSCs to func-
tion as an M1-type cell with a pro-inflammatory re-
sponse [46], whereas the 25 M dose may be the optimal
concentration of cells which gives rise to an M2-type
MSC with an anti-inflammatory/immunosuppressive
response. Hence, which cell dose will lead to the best
outcome cannot be determined until a series of dose-
finding studies are carried out.
Various studies are ongoing to determine the optimal
tissue source of MSCs for therapeutic repair of the car-
tilage tissue. The combination of MSCs with scaffolds,
growth factors, platelet-rich plasma (PRP), and genetic
modification have also been studied. It is not clear which
source of stem cells, or a combination product, will be
the best for the disease condition. Studies have shown
that adipose tissue-derived stem cells are both safe and
efficacious [13, 14, 47–49], whereas other studies haveshown that bone marrow-derived cells are equally effica-
cious [10, 11, 50–52]. A current focus for knee cartilage
repair is to use scaffolds that provide a three-dimensional
environment for guiding and supporting the cells for car-
tilage repair. An advantage for using a scaffold is contain-
ment of the implanted cells on the lesion, and these
biomaterials may act as barriers for fibroblast invasion of
the graft [53, 54]. Koh et al. have used PRP as a scaffold as
it acts as an MSC accelerator for clinical chondrogenesis,
is non-immunogeneic and bioabsorbable, and can be eas-
ily prepared preoperatively [13]. In another study, fibrin
glue has been used as a scaffold in MSC implantation to
induce improved cell survival, proliferation, gene expres-
sion, differentiation, and matrix synthesis leading to repair
of the cartilage lesion [55]. Cartistem® (MEDIPOST Co.
Ltd., South Korea) is a combination product of human
umbilical cord blood-derived mesenchymal stem cells and
hyaluronic acid [56]. This acts as a biodegradable matrix
in MSC implantation as it facilitates the migration and ad-
herence of cells to the damaged cartilage, leading to better
healing of the damaged lesion. Hence, more studies are re-
quired to pinpoint the best source of stem cells and the
scaffold to be used to demonstrate both safety and
efficacy.
The method of delivery of cells—either by direct intra-
articular injection or by open arthroscopy injection—into
the joint cavity is also important and may be one of the
factors for deriving efficacy. In one of the initial studies,
Wakitani et al. transplanted cells of bone marrow embed-
ded in collagen gel into the articular cartilage defect at the
time of high tibial osteotomy [43]. Cartistem®, a combin-
ation product approved by the Korean FDA, has been
applied to the damaged area through arthroscopy after
conducting a microfracture [57]. These open surgical
methods have their disadvantages such as pain, longer
hospital stay, and higher cost. Minimally invasive tech-
niques such as intra-articular injection have been adopted
by different groups [14, 15, 41, 45, 50]. IA injection is
patient-friendly in terms of being less invasive, with re-
duced hospital stay, and are likely to reach a larger patient
population as it can be performed in peripheral hospitals.
Ultrasound guidance of knee injections could be a better
option to more precisely deliver the cells intra-articularly.
Berkoff et al. have reported that ultrasound guidance of
knee injections resulted in better IA accuracy of needle
placement than anatomical guidance (95.8% versus 77.8%;
P < 0.001) [58]. This enhanced injection accuracy achieved
with ultrasound needle guidance directly improves
patient-related clinical outcomes. However, in developing
countries, ultrasound-guided intra-articular injection may
be a challenge due to limited access to the instrument.
The present study, though it has shown good subject-
ive improvement in pain and functional scores, did not
demonstrate improvement in cartilage signal and
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ing system, which is a semiquantitative MRI system for
evaluating structural change in knee OA. WORMS scor-
ing has been extensively studied for the prevalence and
severity of cartilage loss, bone marrow lesions, and
meniscal damage [59, 60], and has seldom been studied
for cartilage regeneration. Koh et al. studied the effect of
adipose-derived MSCs with PRP in OA of the knee joint
and found that WORMS score significantly improved
from 60.0 points to 48.3 points and cartilage subscore
improved from 28.3 points to 21.7 points at 24 months
follow-up (P < 0.001) as compared to baseline [13]. How-
ever, in our study, the cartilage subscore did not demon-
strate any significant worsening or improvement of the
cartilage in any of the subgroups. The reason for the
WORMS score differences between these two studies
could be due to several reasons: the type of MSCs used
are different, better complementarity between adipose-
derived MSC and PRP, or the length of follow-up time
(24 months vs. 12 months) after cell administration. The
limited number of patients used in this study for MRI
analysis might have contributed as well. Regardless of
these differences, Stempeucel® administration in the pre-
clinical model clearly suggested the ability of these cells
in combination with HA to trigger adequate proteogly-
can synthesis for cartilage repair. Future clinical trials of
Stempeucel® in OA patients should consider using
guided delivery of cells in and around the lesion site or
by arthroscopy, followed by MRI measurements using
delayed gadolinium-enhanced MRI of cartilage (dGEM-
RIC) or T2 mapping to perform compositional (sGAG)
analysis of the cartilage before and after cell administra-
tion. One of the limitations of this study was unblinding
of the trial after 6 months follow-up, particularly given
that the subjective measurements of clinical data (VAS,
WOMAC, and ICOAP) were the secondary endpoints.Conclusions
This clinical study satisfied the primary endpoints of
safety of Stempeucel® administration in OA patients at
all four doses tested. In addition, a trend towards pain
reduction at the lowest cell dose of 25 M was observed
by VAS, WOMAC, and ICOAP pain scoring criteria, but
this was not statistically significant when compared to
placebo. Analysis of the remaining secondary endpoints
did not reveal therapeutic efficacy which could be attrib-
uted to the low number of patients enrolled in the study.
The fact that a pooled population of allogeneic BMMSCs
could elicit pain reduction and cartilage regeneration in
a preclinical model of OA coupled with the safety profile
observed in human patients with a positive trend in pain
reduction (in one of the cell doses tested) warrants fur-
ther study in a large number of patients to investigatethe therapeutic role of Stempeucel® in cartilage regener-
ation in OA patients.
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